The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Promising for Monitoring and Diagnosis of AD is the finger-prick test.

2.

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

3.

Biocomputer From Human Neurons Plays Doom, Raises Ethics

4.

Artificial intelligence is assisting in the earlier detection and treatment of breast cancer.

5.

Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot